Literature DB >> 33108657

Methods for the Construction of Recombinant Oncolytic Myxoma Viruses.

Lino E Torres-Domínguez1, Ana Lemos de Matos1, Masmudur M Rahman1, Grant McFadden2,3.   

Abstract

Myxoma virus (MYXV) has proven to be an effective candidate for oncolytic virotherapy in many preclinical cancer models. As a nonhuman pathogen, MYXV does not need to overcome any preexisting antiviral immunity, and its DNA cannot integrate into the host genome, making it an extremely safe vector. Moreover, the large dsDNA genome of MYXV allows the insertion of multiple transgenes and the design of engineered recombinant oncolytic viruses (OVs) with enhanced immunostimulatory or other desired properties. In this chapter, we describe detailed protocols for the generation and characterization of transgene-armed recombinant MYXV vectors.

Entities:  

Keywords:  Armed oncolytic virus; Engineered virus; Myxoma virus; Oncolytic virotherapy; Oncolytic virus; Poxvirus; Recombinant virus; Viral vector

Mesh：

Substances：

Year:  2021        PMID： 33108657      PMCID： PMC8082691          DOI： 10.1007/978-1-0716-1012-1_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  13 in total

1.  Myxoma virus: propagation, purification, quantification, and storage.

Authors:  Sherin E Smallwood; Masmudur M Rahman; Dorothy W Smith; Grant McFadden
Journal:  Curr Protoc Microbiol       Date:  2010-05

2.  Oncolytic Poxviruses.

Authors:  Winnie M Chan; Grant McFadden
Journal:  Annu Rev Virol       Date:  2014-09-01       Impact factor: 10.431

3.  Methods for Identifying Virus-Derived Serpins.

Authors:  Masmudur M Rahman
Journal:  Methods Mol Biol       Date:  2018

4.  Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.

Authors:  Mee Y Bartee; Katherine M Dunlap; Eric Bartee
Journal:  Cancer Res       Date:  2017-03-17       Impact factor: 12.701

5.  Easy and efficient protocols for working with recombinant vaccinia virus MVA.

Authors:  Melanie Kremer; Asisa Volz; Joost H C M Kreijtz; Robert Fux; Michael H Lehmann; Gerd Sutter
Journal:  Methods Mol Biol       Date:  2012

6.  Poxvirus oncolytic virotherapy.

Authors:  Lino E Torres-Domínguez; Grant McFadden
Journal:  Expert Opin Biol Ther       Date:  2019-04-04       Impact factor: 4.388

Review 7.  Oncolytic myxoma virus: the path to clinic.

Authors:  Winnie M Chan; Masmudur M Rahman; Grant McFadden
Journal:  Vaccine       Date:  2013-05-29       Impact factor: 3.641

Review 8.  Immunotherapeutic potential of oncolytic vaccinia virus.

Authors:  Steve H Thorne
Journal:  Front Oncol       Date:  2014-06-17       Impact factor: 6.244

9.  Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity.

Authors:  Vesna Tosic; Diana L Thomas; David M Kranz; Jia Liu; Grant McFadden; Joanna L Shisler; Amy L MacNeill; Edward J Roy
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

Review 10.  Poxvirus tropism.

Authors:  Grant McFadden
Journal:  Nat Rev Microbiol       Date:  2005-03       Impact factor: 60.633
View more
  1 in total

1.  Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma.

Authors:  Joanna Jazowiecka-Rakus; Aleksander Sochanik; Agata Hadryś; Wojciech Fidyk; Ewa Chmielik; Masmudur M Rahman; Grant McFadden
Journal:  Cancers (Basel)       Date:  2022-04-16       Impact factor: 6.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.